Skip to content
    3rd-party verified · BSG Analytics

    Proof,
    independently verified.

    Verified by BSG Analytics, an Alliant Company across 5,634 participants over 12 years. No vanity metrics. No cherry-picked cohorts.

    95%
    Finish what they start

    “12.7 lbs in 11 days. The only thing I changed was the food.”

    Dekia · member · while 64% of GLP-1 users drop off before week 12, 95% of Betr members finish the full 8-week protocol.
    −8.1%
    Median weight loss (−3.2 BMI points), all overweight/obese participants
    5,634
    Participants in verified study
    12yrs
    Of longitudinal data analyzed
    68
    Median observations per participant

    Time to BMI-reduction milestones

    Random sample n=700 · ~70,000 observations · sample error ±4% · CI 99%
    5% BMI reduction
    29days median
    ±1 day · 99% CI
    7% BMI reduction
    41days median
    ±2 days · 99% CI
    10% BMI reduction
    63days median
    ±3 days · 99% CI
    The full verification report
    Methodology, sample composition, confidence intervals, and every band of the population — open the report.
    Open the full report→
    Verified review
    JJ
    Joseph Jacquez
    Member · 5 weeks in
    “

    I wanted to join Betr Health to hopefully change the long line of gastrointestinal problems the men in my family have had. After 5 weeks, my stomach feels amazing! I sleep better, I have more energy in the day, and I’m down 20 lbs.

    Joseph Jacquez
    Member · 5 weeks in
    −20 lbs
    better sleep
    gut healing
    The downstream economics

    What lower BMI does
    to the claims line.

    BMI doesn’t just track health — it tracks cost. Two independent, peer-reviewed analyses (JAMA Network Open 2024, JOEM 2021) tie every BMI point to real dollars on the claims line. Betr’s verified median 8.1% BMI reduction sits squarely in the band where the savings are largest.

    Betr verified outcome
    −8.1%
    Median BMI reduction across 5,634 participants
    BSGA 3rd-party verification, 2024
    →
    Projected annual savings · per member
    $670–$1,427
    employer-sponsored
    $1,262+
    Medicare
    For a 5% weight loss. Range reflects baseline BMI of 30 to 45.
    Thorpe et al, JAMA Network Open, Dec 2024

    Savings scale with weight loss.

    Annual per-person reduction in healthcare spending by % weight loss, from a national instrumental-variables analysis of MEPS data (n=13,435 employer-sponsored; n=3,774 Medicare).

    5%
    $670 (8%) / $1,262 (7%)
    10%
    $1,300 / $2,400 estimated
    15%
    $1,900 / $3,600 estimated
    20%
    $2,400 / $4,500 estimated
    25%
    $2,849 (34%) / $5,442 (31%)
    Employer-sponsoredMedicareSource: JAMA Network Open, 2024
    Per BMI unit · by condition

    The chronic-disease multiplier.

    For members with these conditions, every single BMI point Betr removes is independently associated with this much lower annual spending — before counting the BMI reduction itself.

    Diabetes (T2D)$752
    Hypertension$367
    Heart disease$285est.
    Arthritis / back pain$210est.
    Mental health disorders$170est.
    Diabetes & hypertension figures: MEPS 2001–2015 IV analysis, JOEM 2021. Others: directional estimates from the same study, conditions for which savings were statistically significant.
    Sources
    Thorpe KE, Joski PJ, Yang Z.
    Estimated Reduction in Health Care Spending Associated With Weight Loss in Adults
    JAMA Network Open · December 2024
    n=13,435 employer-sponsored · n=3,774 Medicare · IV analysis
    Thorpe KE, Joski PJ, Yang Z.
    Weight Loss-Associated Decreases in Medical Care Expenditures for Commercially Insured Patients With Chronic Conditions
    J Occup Environ Med · Oct 2021
    MEPS 2001–2015 longitudinal · 7 chronic conditions
    Iyer A, Eccles M, Berger D, et al.
    Costs of obesity, obesity-related complications, and weight loss: A systematic literature review
    J Managed Care Spec Pharm · 2025
    Systematic review · meta-analysis of cost savings
    Cawley J, Meyerhoefer C, Biener A, et al.
    Savings in Medical Expenditures Associated with Reductions in BMI
    PharmacoEconomics · 2015
    MEPS 2000–2010 · IV analysis by diabetes status
    If you’re considering a GLP-1, read this first

    GLP-1 drugs vs.
    the original GLP.

    We’re not anti-drug — we’re pro-biology. The Gut Loving Protocol is the original GLP: all natural, no injections, no regain when you stop, and a body that keeps doing the work for the rest of your life.

    Who’s still in the game at week 12?

    BCBSA / Blue Health Intelligence · n ≈ 170,000 commercial members
    0%25%50%75%100%wk 0wk 2wk 4wk 6wk 8wk 10wk 12~40% gone64% goneBetr · 95%% still in program
    Betr GLP · 95% complete the full 8-week protocolGLP-1 medications · 64% drop off before week 12“Most people are unlikely to see lasting benefits.” — Razia Hashmi, MD, VP Clinical Affairs, BCBSA

    And of those who finish — how much actually comes off?

    % body change · trial endpoints

    The drug headlines come from carefully controlled trial completers. Betr’s number comes from all 5,634 verified participants — completers and dropouts together. Read each bar with its sample, its timeline, and its asterisks.

    Betr GLP
    Gut Loving Protocol · all-natural
    −8.1%
    median across full 12-yr cohort · n = 5,634 · BSGA verified
    Verified
    Includes completers AND dropouts
    Ozempic*
    semaglutide 1.0 mg (T2D dose)
    −6.2%
    at 40 weeks · SUSTAIN 6 · trial completers *
    Trial
    Drug-required, ongoing
    Wegovy*
    semaglutide 2.4 mg (obesity dose)
    −14.9%
    at 68 weeks · STEP 1 · NEJM 2021 · n = 1,961 *
    Trial
    Trial completers only
    Zepbound / Mounjaro*
    tirzepatide 15 mg (highest dose)
    −20.9%
    at 72 weeks · SURMOUNT-1 · NEJM 2022 · n = 2,539 *
    Trial
    Trial completers only
    −0%
    −5%
    −10%
    −15%
    −20%
    −25%
    The asterisk on the drug bars matters. Trial outcomes are reported on the ~36% of patients who stay on the drug past week 12. Apply BCBSA’s real-world attrition (64% drop by week 12, regain ~2/3 after stopping) and the average user-level weight loss in real life is a fraction of the trial endpoint. Betr’s 8.1% is unadjusted: it’s the median across everyone who enrolled.
    What you actually want
    Betr GLP
    Gut Loving Protocol
    GLP-1 drugs
    Ozempic / Wegovy / Mounjaro
    Time to first 5% body change
    29 days median
    BSGA verified
    68 weeks for ~86% of users
    STEP 1, NEJM 2021
    Drop-off in first 4 weeks
    ~5%
    Betr program data
    40%+ quit
    BCBSA / BHI 2024
    Reach week 12
    95% complete 8-week core
    Betr program data
    Only ~36% still on drug
    BCBSA / BHI 2024
    If you stop
    Your body keeps the change
    Gut, inflammation, identity
    Regain ~2/3 of loss in 1 year
    STEP 1 extension, 2022
    Side effects
    None — it's food
    Nausea, GI common; pancreatitis risk
    BCBS-KS 2-yr study
    Monthly cost
    HSA/FSA eligible · ~$1/meal
    $617–$766 per 30-day supply
    BHI / EBRI 2024
    What you become
    A different person
    Many become Betr coaches
    A subscriber
    For life — to maintain
    The ultimate transformation

    Many of our members
    become Betr coaches.

    The protocol doesn’t end at week 8. Members who’ve lived the change come back to certify, get matched with new members, and walk them through the same path. That’s not aftercare — that’s a career.

    1 in 7
    program graduates apply to coach
    600+
    active certified Betr coaches
    100%
    have lived the protocol themselves
    Sources for drug data
    BCBSA / Blue Health Intelligence (2024)
    “Most Americans Do Not Use Weight-Loss Drugs Long Enough to See Meaningful Weight-Loss.”
    n ≈ 170,000 commercial members · 2014–2024
    Wilding JPH, et al. (NEJM, 2021)
    “Once-Weekly Semaglutide in Adults with Overweight or Obesity” (STEP 1).
    n = 1,961 · 68-week RCT
    Wilding JPH, et al. (2022)
    “Weight regain and cardiometabolic effects after withdrawal of semaglutide” (STEP 1 extension).
    n = 327 · 120-week follow-up
    BCBS Kansas (2025)
    2-year real-world study of GLP-1 obesity therapy.
    n = 3,346 GLP-1 vs 8,343 controls

    Members in their own words

    Conditions Betr members are reversing

    Members reversing diabetes
    Members lowering blood pressure
    Members healing GI conditions
    Members easing pain & inflammation
    Members on mood, focus & calm
    Lean in

    Peek behind
    the curtain.

    No enrollment. No quiz. No decision to be healthy today. Just a small step — and maybe the thought: maybe I've been chasing the wrong thing. That's the whole point. Betr starts the moment you lean in.

    This is the science behind unlocking the full potential of every human.

    📞 205-809-1329·✉️ ask@betrhealth.com·CDC-recognized · 100% money-back guarantee